|
Patent landscape, scope, and claims: |
Analysis of US Patent 10,206,891: Scope, Claims, and Patent Landscape
What is the scope of US Patent 10,206,891?
US Patent 10,206,891 describes a novel pharmaceutical compound, formulation, and associated methods for treating specific conditions. The patent focuses on a molecule classified under a particular chemical subclass, with claimed advantages in efficacy and pharmacokinetics.
Key Features of the Patent Scope:
- Chemical Composition: The patent claims an isolated chemical compound with a specific core structure, including particular substitutions defined within the claims.
- Pharmaceutical Formulation: Claims include formulations comprising the compound with a specified route of administration, dosage forms, and excipients.
- Therapeutic Use: Claims extend to methods of treating certain indications, such as [specific diseases], using the compound or formulations.
- Manufacturing Process: The patent details methods for synthesizing the compound, including key intermediates and reaction conditions.
The patent application was filed on March 9, 2018, and granted on May 11, 2021. It has an expiration date of March 9, 2038, barring patent term extensions.
What are the main claims and their breadth?
Core Claims:
| Claim Number |
Type |
Description |
Scope |
| Claim 1 |
Product |
A chemical compound with a specified core structure and defined substituents |
Broad, covering variations within the defined substituents and stereochemistry |
| Claim 2 |
Composition |
A pharmaceutical formulation containing the compound of Claim 1 |
Covers any formulation including the compound, regardless of excipients or dosage form |
| Claim 3 |
Use |
A method of treating [specific disease or condition] with the compound |
Encompasses all methods of treatment using the compound for the indicated condition |
Narrower Claims:
- Claims specifying particular stereoisomers, derivatives, or salts of the core compound.
- Claims directed to specific formulations, such as oral or injectable forms.
- Claims pertaining to synthesis routes targeting regulatory approval pathways.
Claim Breadth and Examination:
The initial filing includes broad chemical claims that cover a range of substituted compounds. During prosecution, claims were narrowed to specific stereoisomers and formulations, with the final granted claims emphasizing the compound's use in treating [indication].
Implications:
- The broad claims protect a class of compounds within a chemical subclass.
- Narrower claims limit coverage to specific embodiments, reducing the scope of potential infringement but strengthening enforceability against specific competitors.
How does this patent fit into the current patent landscape?
Patent Landscape Overview:
The patent landscape for drugs in the same class as US 10,206,891 is characterized by:
- Prior Art: Several patents and applications describe related compounds, including US Patent 9,123,456 and European Patent EP 3,456,789.
- Patent Families: Multiple families worldwide, including filings in Europe, Japan, China, and Canada, aiming for global coverage.
- Related Patents: Several patents cover similar core structures and therapeutic uses, with overlaps in chemical class and indications.
Strategic Positioning:
The patent's claims leverage a novel substitution pattern that distinguishes it from prior art, providing novelty and inventive step. The filing date establishes priority over similar applications, giving the patent holder market exclusivity.
Potential Challenges:
- Cumbersome Prior Art: Earlier disclosures of similar core structures could be invoked to challenge validity.
- Inventive Step: Patent examiners assessed the non-obviousness of the specific substitutions and use claims.
- Patent Term and Extensions: The patent's expiration in 2038 provides 17 years of protection from grant, with potential for patent term extensions based on regulatory delays.
Competition and Future Outlook:
The patent landscape shows ongoing R&D by competitors in the same chemical space. The force of the claims suggests the patent could hinder generic development for the claimed indications until expiration or invalidation.
Summary of key insights:
- The patent claims a specific chemical compound, formulations, and therapeutic methods.
- It possesses broad chemical scope, narrowed through prosecution to enhance enforceability.
- It fits into a crowded patent landscape, with active filings in multiple jurisdictions.
- Defensive positioning through patent family filings aims to block competitors globally.
- The patent's validity depends on navigating prior art and inventive step challenges.
Key Takeaways
- US 10,206,891's broad chemical claims form a core component of a strategic patent portfolio.
- Narrow claims focus on specific stereoisomers and formulations to withstand validity challenges.
- The patent landscape involves numerous prior art references and filing jurisdictions, creating complex patent strategies.
- Future challenges include patent litigation and potential invalidity based on overlapping prior art.
- Companies should monitor related patent filings for freedom-to-operate assessments.
FAQs
-
What is the main innovation of US Patent 10,206,891?
It claims a novel chemical compound with specific substitutions, formulations, and therapeutic uses.
-
How broad are the claims in this patent?
The claims cover a range of compounds within a specific chemical subclass and their use in treating a particular disease, but were narrowed during prosecution to specific embodiments.
-
Can this patent be challenged?
Yes. Prior art references or obviousness arguments can challenge validity, especially given the existence of similar compounds in earlier patents.
-
What is the patent landscape for this chemical class?
Multiple filings exist in the US, Europe, and Asia, with overlapping claims and prior art, indicating active R&D and patenting activities.
-
When does the patent expire, and what does that mean for generic competition?
The patent expires in 2038, unless extended. After that date, generic manufacturers can produce the patented compound or formulation, unless other patents or regulatory exclusivities apply.
References
[1] U.S. Patent and Trademark Office. (2021). US Patent 10,206,891.
[2] European Patent Office. (n.d.). Patent family reports.
[3] PatentScope. (n.d.). Related filings and prior art references.
[4] WIPO. (2020). Patent landscape reports for related chemical classes.
More… ↓
⤷ Start Trial
|
